Dainippon Of Japan Begins Final Trials Of Enhanced Schizophrenia Drug
This article was originally published in PharmAsia News
Executive Summary
Japan's Dainippon Sumitomo Pharma is beginning the second of three Phase III trials of its schizophrenia drug it says has survived all tests so far. The drug's active pharmaceutical ingredient is lurasidone, intended to be a competitor of Eli Lilly's Zyprexa (olanzapine) and AstraZeneca's Seroquel (quetiapine). The final two Phase III trials are intended to test lurasidone against those two drugs, with a target of completing the trials by year-end and submitting applications to U.S. FDA next year. In addition to test the drug against the two big sellers, Dainippon also is testing its efficacy for improving cognitive functions. (Click here for more - a subscription may be required